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BACKGROUND
The safety and efficacy of antenatal glucocorticoids in women in low-resource 
countries who are at risk for preterm birth are uncertain.
METHODS
We conducted a multicountry, randomized trial involving pregnant women between 
26 weeks 0 days and 33 weeks 6 days of gestation who were at risk for preterm birth. 
The participants were assigned to intramuscular dexamethasone or identical pla-
cebo. The primary outcomes were neonatal death alone, stillbirth or neonatal 
death, and possible maternal bacterial infection; neonatal death alone and still-
birth or neonatal death were evaluated with superiority analyses, and possible 
maternal bacterial infection was evaluated with a noninferiority analysis with the 
use of a prespecified margin of 1.25 on the relative scale.
RESULTS
A total of 2852 women (and their 3070 fetuses) from 29 secondary- and tertiary-
level hospitals across Bangladesh, India, Kenya, Nigeria, and Pakistan underwent 
randomization. The trial was stopped for benefit at the second interim analysis. 
Neonatal death occurred in 278 of 1417 infants (19.6%) in the dexamethasone 
group and in 331 of 1406 infants (23.5%) in the placebo group (relative risk, 0.84; 
95% confidence interval [CI], 0.72 to 0.97; P = 0.03). Stillbirth or neonatal death 
occurred in 393 of 1532 fetuses and infants (25.7%) and in 444 of 1519 fetuses 
and infants (29.2%), respectively (relative risk, 0.88; 95% CI, 0.78 to 0.99; P = 0.04); 
the incidence of possible maternal bacterial infection was 4.8% and 6.3%, respec-
tively (relative risk, 0.76; 95% CI, 0.56 to 1.03). There was no significant between-
group difference in the incidence of adverse events.
CONCLUSIONS
Among women in low-resource countries who were at risk for early preterm birth, 
the use of dexamethasone resulted in significantly lower risks of neonatal death 
alone and stillbirth or neonatal death than the use of placebo, without an increase 
in the incidence of possible maternal bacterial infection. (Funded by the Bill and 
Melinda Gates Foundation and the World Health Organization; Australian and 
New Zealand Clinical Trials Registry number, ACTRN12617000476336; Clinical 
Trials Registry–India number, CTRI/2017/04/008326.)
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Preterm birth is a leading cause of death in infants and children younger than 5 years of age globally.1 Infants born pre-
term are also at increased risk for a wide range 
of short-term and long-term respiratory, infec-
tious, metabolic, and neurologic conditions, with 
higher risks among those born during the early 
preterm period.2,3
On the basis of trials conducted largely in 
high-resource countries, antenatal glucocorticoids 
have long been promoted as the key intervention 
for reducing preterm infant mortality and mor-
bidity.4,5 However, the generalizability of this 
evidence to low-resource settings was called into 
question in 2015, when a large population-based 
trial conducted in six low-resource countries 
showed that efforts to scale up the use of ante-
natal glucocorticoids could lead to harm.6 In 
that trial, scaling up of glucocorticoids did not 
reduce mortality among infants who were below 
the fifth percentile for birth weight (a proxy for 
preterm birth) and unexpectedly was associated 
with an increase in the incidence of neonatal 
death, stillbirth, and suspected maternal infection 
in the population overall. These findings reopened 
the debate about the safety and efficacy of ante-
natal glucocorticoids in low-resource countries.7,8
Because of these considerations, in 2015 the 
World Health Organization (WHO) recommend-
ed that antenatal glucocorticoids should be used 
only under certain conditions, including the ac-
curate assessment of gestational age, imminent 
preterm birth, the absence of maternal infection, 
and adequate care for childbirth and preterm 
newborns.9 The guideline panel and an expert 
panel that was subsequently convened by the 
WHO identified the conduct of efficacy trials in 
hospitals in low-resource countries as a research 
priority in order to resolve this controversy and 
guide clinicians and policymakers on the use of 
antenatal glucocorticoids.7,8 We conducted the 
WHO ACTION-I (Antenatal Corticosteroids for 
Improving Outcomes in Preterm Newborns) trial, 
a randomized trial to assess the safety and effi-
cacy of dexamethasone in women in hospitals in 
low-resource countries who were at risk for 
early preterm birth.
Me thods
Trial Design and Oversight
We designed a multicountry, multicenter, parallel-
group, double-blind, individually randomized, pla-
cebo-controlled trial to compare intramuscular 
dexamethasone with identical placebo in women 
at risk for imminent preterm birth. We conducted 
the trial at 29 secondary- and tertiary-level hos-
pitals across six trial sites in Bangladesh, India, 
Kenya, Nigeria, and Pakistan. The trial protocol, 
which has been published previously,10 is avail-
able with the full text of this article at NEJM.org. 
It was approved by the relevant ethics commit-
tees and regulatory agencies in each country and 
by the WHO Ethics Review Committee. WHO was 
the trial sponsor. A steering group comprising a 
trial coordinating unit, principal investigators, 
and technical advisors provided trial oversight.
Fresenius Kabi–Labesfal (Portugal) produced 
dexamethasone sodium phosphate and identical 
placebo, which were packaged and shipped to the 
trial sites by Ivers–Lee Clinical Supplies Manage-
ment (Switzerland). Fresenius Kabi–Labesfal had 
no role in the trial design, the collection, analy-
sis, and interpretation of the data, the writing of 
the manuscript, or the decision to submit the 
manuscript for publication. The first, second, 
third, and seventh members of the writing com-
mittee vouch for the accuracy and completeness 
of the data and for the fidelity of the trial to the 
protocol.
Trial Setting
The trial hospitals were selected through a stan-
dardized assessment of maternal and newborn 
health care services (Table S1 in the Supplemen-
tary Appendix, available at NEJM.org) to ensure 
that the WHO criteria for antenatal glucocorti-
coid treatment could be reasonably met.8,9 To 
make the trial procedures consistent and to en-
sure that the trial participants received at least 
the minimum quality of care, ultrasonographic 
systems (Philips HD5, the Netherlands), contin-
uous positive airway pressure (CPAP) machines 
(DiaMedica UK, United Kingdom), pulse oxim-
eters (Masimo International, Switzerland), and 
glucometers were procured for all the hospitals. 
Standardized training was provided to all re-
search and clinical staff.
Screening and Recruitment
Pregnant women who had confirmed live fetuses 
between 26 weeks 0 days and 33 weeks 6 days of 
gestation and who were at risk for preterm birth 
were eligible for inclusion. The inclusion criteria 
were planned or expected birth in the next 48 
hours (either provider-initiated preterm birth or 
The New England Journal of Medicine 
Downloaded from nejm.org on October 5, 2021. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
n engl j med 383;26 nejm.org December 24, 20202516
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
after preterm, prelabor rupture of membranes or 
spontaneous labor). Gestational age was deter-
mined by the earliest ultrasonographic exami-
nation or an ultrasonographic examination per-
formed at admission. Women were excluded if 
they had clinical signs of severe infection, major 
congenital fetal anomalies, concurrent or recent 
(within the previous 2 weeks) use of systemic 
glucocorticoids, or a contraindication to gluco-
corticoids or if they were participating in another 
trial. Written informed consent was obtained 
from all the participants before randomization.
Randomization and Trial Regimens
The participants were randomly assigned in a 
1:1 ratio to a course of intramuscular injections 
of either 6 mg of dexamethasone or identical 
placebo administered every 12 hours, for a maxi-
mum of four doses, or until hospital discharge 
or birth. The women were eligible for a repeat 
course if they had not given birth after 7 com-
pleted days but still met the inclusion criteria. 
The repeat course was identical to the first course 
and the same as the initial assignment.
Site-stratified individual randomization with 
balanced permuted blocks of 10 were used. The 
computer-generated randomization sequence was 
prepared centrally at the WHO. All the sites re-
ceived serially numbered identical packs con-
taining ampules of 4 mg per milliliter of dexa-
methasone or placebo for two full courses. The 
trial participants, care providers, and investiga-
tors were unaware of the trial-group assignments.
The participants received either dexametha-
sone or placebo immediately after randomiza-
tion. Clinical care was provided according to 
local guidelines. Follow-up of the fetuses was 
conducted until 28 days after birth or until death 
(stillbirth or neonatal death), whichever came 
first, and follow-up of the women was conduct-
ed until 28 days after they gave birth or until 
death, whichever came first. Trained research 
staff collected data during the hospital admis-
sion or admissions and during community-level 
visits.
Trial Outcomes
The three primary outcomes were neonatal 
death (death of a live-born infant within 28 com-
pleted days of life), stillbirth or neonatal death, 
and a composite of possible maternal bacterial 
infection, defined as maternal fever (tempera-
ture ≥38°C) or clinically suspected or confirmed 
infection for which therapeutic antibiotics were 
used. The secondary outcomes were maternal and 
newborn mortality and morbidity as well as 
process-of-care outcomes (a list and definitions 
of these outcomes are provided in the Statistical 
Methods section in the Supplementary Appendix).
All trial-related information was stored se-
curely at the trial sites. Data were double-entered 
into a Web-based data-management platform and 
centrally managed by Centro Rosarino de Estu-
dios Perinatales (Argentina).
Statistical Analysis
We estimated that 6018 women would have to be 
recruited to detect a decrease in the risk of neo-
natal death of 15.00% or more, from 25.00% to 
21.25%, in a two-sided 5% significance test with 
90% power and 10% loss to follow-up. The esti-
mated sample size would provide more than 
80% power at the 2.5% significance level to de-
tect whether dexamethasone is noninferior to 
placebo for maternal infection, within a nonin-
feriority margin of 1.25 on the relative scale. The 
noninferiority margin was based on the consid-
eration that a maximum increase of 25% over a 
10% baseline incidence of maternal bacterial 
infection could be accepted for a fetal or infant 
mortality benefit.
For the primary outcomes, intention-to-treat 
analyses were to be performed. We hypothesized 
that the use of dexamethasone would result in a 
decrease in the risk of neonatal death and still-
birth or neonatal death without increasing the 
risk of maternal infection. Therefore, we applied 
a superiority hypothesis to neonatal death and 
stillbirth or neonatal death, and we applied a 
noninferiority hypothesis to maternal infection. 
Analyses were first performed on all available 
data, and sensitivity analyses were then per-
formed with the use of multiple imputation11 to 
judge the effect of missing data. Analyses of 
primary outcomes were corrected for multiplici-
ty with the false-discovery-rate approach.12 The 
dexamethasone group was compared with the 
placebo group for the primary outcomes with 
the use of relative risks with 95% confidence 
intervals, according to a logistic model with a 
binomial distribution and a log link to obtain 
relative risks. The stratifying variable — trial site 
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— was included in the model, as well as a clus-
tering feature for multiple births for neonatal 
outcomes. For continuous variables, means and 
standard deviations or medians and interquartile 
ranges according to group were reported. The 
trial groups were compared with mean or median 
differences and 95% confidence intervals ac-
cording to a general linear model that included 
trial site as the stratifying variable. Separate 
models were fitted for each of the primary and 
secondary outcomes.
The primary outcomes were analyzed in pre-
specified subgroups (see the Statistical Methods 
section in the Supplementary Appendix). The 
results for all secondary outcomes and subgroup 
analyses are presented as point estimates and 
95% confidence intervals. No correction was made 
for multiplicity, and the width of the confidence 
intervals should not be used to infer treatment 
effects. All the models were fitted with the use of 
SAS software, version 9.4 (SAS Institute).
Three interim analyses by the data and safety 
monitoring board were planned. The board mem-
bers were to inform the steering group chair if, 
in their view, there was proof beyond a doubt 
that dexamethasone was indicated or contrain-
dicated on the basis of statistical considerations 
(using the Haybittle–Peto stopping rule13 for the 
primary outcomes for fetuses and infants) or 
clinical considerations, practical issues, or new 
external information. After the second interim 
analysis involving 2304 women and 2536 fetuses 
and infants, with complete follow-up of primary 
outcomes, the data and safety monitoring board 
decided to unblind the trial and recommended 
that the trial be stopped for fetus and infant 
mortality benefits and strong evidence of a 
graded dose–response effect, in the context of 
existing evidence of benefits of antenatal gluco-
corticoids.4 Recruitment was stopped across all 
sites on November 21, 2019, and all ethics com-
mittees and regulatory authorities were informed. 




From December 2017 through November 2019, 
of the 7008 women who were screened for eligi-
bility, 2852 underwent randomization (1429 to 
the dexamethasone group and 1423 to the pla-
cebo group) (Fig. 1). The most common reason 
for ineligibility was that birth was not planned 
or expected in the next 48 hours. A total of 
90.0% of the infants in the dexamethasone 
group and 90.8% of those in the placebo group 
were born before 37 weeks. More than 99.0% of 
the women who underwent randomization and 
their infants completed follow-up. The charac-
teristics of the dexamethasone and placebo 
groups were similar at trial entry (Table 1 and 
Table S2).
Adherence to Assigned Trial Regimen
All the women except 1 received at least one dose 
of dexamethasone or placebo (Fig. 1). A total of 
815 of 1429 women (57.0%) in the dexametha-
sone group and 756 of 1423 women (53.1%) in 
the placebo group received all four doses in the 
first course. The repeat course was administered 
to 61 women in the dexamethasone group and 
74 women in the placebo group, of whom 46 and 
47 women, respectively, received four doses. The 
most common reason that a scheduled dose was 
not administered was the occurrence of birth 
between the administration of doses.
Primary Outcomes
There were 278 neonatal deaths among 1417 live-
born infants in the dexamethasone group (19.6%) 
and 331 neonatal deaths among 1406 live-born 
infants in the placebo group (23.5%) (relative 
risk, 0.84; 95% confidence interval [CI], 0.72 to 
0.97; P = 0.03) (Table 2). We determined that 25 
women would need to be treated with dexameth-
asone to prevent 1 neonatal death (95% CI, 14 to 
110). The incidence of stillbirth or neonatal death 
was also significantly lower in the dexametha-
sone group than in the placebo group (25.7% vs. 
29.2%; relative risk, 0.88; 95% CI, 0.78 to 0.99; 
P = 0.04).
Possible maternal bacterial infection occurred 
in 68 of 1416 women (4.8%) in the dexametha-
sone group and in 89 of 1412 women (6.3%) in 
the placebo group (relative risk, 0.76; 95% CI, 
0.56 to 1.03; P = 0.002 for noninferiority); this 
result was consistent with noninferiority at the 
prespecified margin of 1.25 (Table 2). In the per-
protocol population, possible maternal bacterial 
infection occurred in 63 of 1393 women (4.5%) 
in the dexamethasone group and in 89 of 1385 
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Figure 1. Screening, Enrollment, Randomization, and Follow-up.
Women could have more than one reason for not meeting eligibility criteria.
2852 Underwent randomization
7008 Women were assessed for eligibility
4156 Were excluded
3914 Did not meet eligibility criteria
256 Did not have fetus with gestational age ≥26 wk
0 days to 33 wk 6 days
514 Did not have fetus or fetuses alive
2604 Did not have birth planned or expected in next 48 hr
104 Had suspected or evidence of clinical
chorioamnionitis
341 Had suspected or evidence of severe acute infection
119 Had fetus with major or lethal malformation
70 Had known contraindication to glucocorticoids
617 Had concurrent use of parenteral glucocorticoids
6 Were enrolled in another clinical trial
229 Did not give consent
13 Had other reasons
7 Delivered before undergoing randomization
5 Had provider who did not have medicine available
1 Had unspecified reason
1429 Women with 1544 fetuses were 
assigned to receive dexamethasone
1428 (99.9%) Received first course
815 (57.0%) Received 4 doses
85 (5.9%) Received 3 doses
147 (10.3%) Received 2 doses
381 (26.7%) Received 1 dose
1 (0.1%) Did not receive any dose
of first course owing to delivery
before the first dose
61 (4.3%) Received repeat course
46 (3.2%) Received 4 doses
2 (0.1%) Received 3 doses
4 (0.3%) Received 2 doses
9 (0.6%) Received 1 dose
1423 Women with 1526 fetuses were
assigned to receive placebo
1423 (100%) Received first course
756 (53.1%) Received 4 doses
80 (5.6%) Received 3 doses
152 (10.7%) Received 2 doses
435 (30.6%) Received 1 dose
74 (5.2%) Received repeat course
47 (3.3%) Received 4 doses
6 (0.4%) Received 3 doses
9 (0.6%) Received 2 doses
12 (0.8%) Received 1 dose
6 (0.4%) Did not receive any dose
of repeat course (declined injection)
9 Women were lost to follow-up owing to
withdrawal from trial
7 Infants were lost to follow-up
5 Could not be located
1 Had family who declined to participate
1 Had mother who withdrew from trial
8 Women were lost to follow-up owing to
withdrawal from trial
12 Infants were lost to follow-up
10 Could not be located
1 Had family who declined to participate
1 Had mother who withdrew from trial
5 Women were not able to be assessed
for primary outcome
2 Women were not able to be assessed
for primary outcome
1416 Women were assessed for primary
outcome
1532 Fetuses and infants were assessed
for primary outcomes
1417 Live-born infants were assessed for
primary outcome
1412 Women were assessed for primary
outcome
1519 Fetuses and infants were assessed
for primary outcomes
1406 Live-born infants were assessed for
primary outcome
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women (6.4%) in the placebo group (relative 
risk, 0.70; 95% CI, 0.51 to 0.96); this result was 
also consistent with noninferiority. Multiple im-
putation for missing values11 yielded identical re-
sults for all the primary outcomes (Table S3).
The results according to the prespecified sub-
groups are shown in Figure 2 and Figure S1. 
Analyses of neonatal death, according to the 
time from the first dose of dexamethasone or 
placebo to birth, stratified according to gesta-
tional age, suggest greater benefit with increas-
ing time from the first dose to birth and increas-
ing gestational age at the first dose (from 26 to 
32 weeks) (Fig. S2). In a post hoc analysis of the 
causes of neonatal death, the frequency of neo-
natal death caused by respiratory distress syn-
drome was lower in the dexamethasone group 
than in the placebo group (Table S4).






Clinical assessment of imminent preterm birth at trial entry — no. (%)
Spontaneously initiated preterm birth 874 (61.2) 858 (60.3)
Preterm prelabor rupture of membranes 455 (31.8) 388 (27.3)
Spontaneous preterm labor 419 (29.3) 470 (33.0)
Provider-initiated preterm birth 555 (38.8) 565 (39.7)
Gestational age at trial entry — wk 30.8±2.0 30.7±2.0
Maternal age — yr 27.5±5.8 27.5±5.9
Fetuses in the current pregnancy — no. (%)
Single 1295 (90.6) 1290 (90.7)
Twin 125 (8.7) 129 (9.1)
Higher-order multiples 9 (0.6) 4 (0.3)
Nulliparous women — no. (%) 529 (37.0) 549 (38.6)
History of preterm birth — no. (%)† 177 (12.4) 188 (13.2)
Obstetrical condition present — no. (%)‡
Gestational diabetes 22 (1.5) 15 (1.1)
Preeclampsia or eclampsia 275 (19.2) 326 (22.9)
Gestational hypertension§ 75 (5.2) 68 (4.8)
Known or suspected oligohydramnios 336 (23.5) 310 (21.8)
Known or suspected polyhydramnios 19 (1.3) 30 (2.1)
Known or suspected intrauterine growth restriction 94 (6.6) 95 (6.7)
Abruptio placentae 49 (3.4) 40 (2.8)
Placenta previa 115 (8.0) 110 (7.7)
Other obstetrical hemorrhage 66 (4.6) 42 (3.0)
No obstetrical condition 616 (43.1) 592 (41.6)
Medication administered before randomization — no. (%)
Tocolytic agent 251 (17.6) 267 (18.8)
Magnesium sulfate for neuroprotection 141 (9.9) 179 (12.6)
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding.
†  This category was assessed only in women with a previous pregnancy.
‡  Women may have had more than one condition.
§  This category excludes preeclampsia and eclampsia.
The New England Journal of Medicine 
Downloaded from nejm.org on October 5, 2021. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
n engl j med 383;26 nejm.org December 24, 20202520
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Secondary Neonatal Outcomes
The results with respect to early neonatal death, 
severe respiratory distress at 24 hours after birth, 
neonatal hypoglycemia at 6 hours after birth, 
major resuscitation at birth, the use of CPAP, 
and the duration of oxygen therapy provide sup-
port for the primary findings. Other secondary 
and process-of-care outcomes were similar in 
the dexamethasone and placebo groups (Table 3 
and Table S5).
Secondary Maternal Outcomes
The secondary maternal outcomes were similar in 
the dexamethasone and placebo groups (Table 3). 
Five women died in the dexamethasone group, 
and four women died in the placebo group.
Adverse Events
Prespecified maternal and neonatal outcomes 
were excluded from the reporting of serious ad-
verse events. There was no significant between-
group difference in the incidence of serious ad-
verse events, which occurred in 1.1% of the 
women in both groups (Table S6). No serious 
adverse events were reported in the neonates.
Discussion
In this hospital-based randomized trial con-
ducted in low-resource countries, we found that 
the administration of dexamethasone to women 
who were at risk for early preterm birth reduced 
the incidences of neonatal death and stillbirth or 
neonatal death without increasing the incidence 
of maternal bacterial infection. Dexamethasone 
had no effect on stillbirth, but the findings for 
several secondary outcomes, including early neo-
natal death, severe respiratory distress, and the 
use of major neonatal resuscitation and CPAP 
were consistent with the overall results for neo-
natal deaths by 28 days. These clinical benefits 
were observed even though 45% of the partici-
pants received fewer than four doses of their 
assigned medication.
Our findings are generally consistent with 
the results of a meta-analysis of 22 trials that 
were mostly conducted in high-resource settings. 
That meta-analysis showed a substantial decrease 
in the incidence of neonatal death among in-
fants of women who received glucocorticoids.4 
Previous efforts to increase the low use of ante-
natal glucocorticoids in women at risk for pre-
term birth in low-resource countries14 were 
challenged by the results of the Antenatal Corti-
costeroids Trial (ACT).6,15 ACT was a cluster-
randomized trial of an implementation strategy 
that included provider training and tools to iden-
tify women who were eligible to receive dexa-
methasone at all levels of care, including primary 
health care and care at the community level.
In contrast to ACT, which selected women for 
treatment on the basis of their last menstrual 
period or measurement of uterine height and 
included clinical settings where resources for 
neonatal care were inadequate, the hospitals in 
our trial selected patients for whom treatment 
Table 2. Primary Outcomes.
Outcome Dexamethasone Placebo
Relative Risk 
 (95% CI)* P Value†
no./total no. (%)
Neonatal death 278/1417 (19.6) 331/1406 (23.5) 0.84 (0.72–0.97) 0.03
Stillbirth or neonatal death 393/1532 (25.7) 444/1519 (29.2) 0.88 (0.78–0.99) 0.04
Possible maternal bacterial 
infection‡
68/1416 (4.8) 89/1412 (6.3) 0.76 (0.56–1.03) 0.002§
*  Relative risks and 95% confidence intervals, calculated from modeling, were adjusted for trial sites and accounted for 
clustering due to multiple births.
†  P values were adjusted for multiplicity for the three primary outcomes with the use of the false-discovery-rate approach.
‡  Possible maternal bacterial infection was defined as the occurrence of fever (temperature ≥38°C) or clinically suspected 
or confirmed infection for which therapeutic antibiotics were used. Suspected or confirmed infection included obstetri-
cal infection (chorioamnionitis, postpartum endometritis, or wound infection) or nonobstetrical infection (respiratory 
tract infection [pneumonia, pharyngitis, sinusitis, or a similar infection], urinary tract infection [excluding pyelonephritis], 
pyelonephritis, acute cholecystitis, or other system infection) captured during hospital admission or admissions only.
§  This P value was calculated for noninferiority.
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was warranted (through assessment by obstetri-
cal physicians and verification of gestational age 
by ultrasonographic examination) and provided 
minimum standards of neonatal care, including 
access to oxygen and CPAP. In the current trial, 
90% of the infants who were exposed to dexa-
methasone were born preterm, whereas only 16% 
of the infants exposed to dexamethasone in the 






Stillbirth 115/1544 (7.4) 113/1526 (7.4) 1.00 (0.78–1.30)
Early death: ≤7 days after birth 218/1417 (15.4) 268/1406 (19.1) 0.81 (0.68–0.96)
Severe respiratory distress‡ 116/1245 (9.3) 141/1223 (11.5) 0.81 (0.64–1.03)
At 24 hr after birth 34/1122 (3.0) 58/1065 (5.4) 0.56 (0.37–0.85)
Sepsis 183/1284 (14.3) 197/1264 (15.6) 0.92 (0.76–1.11)
Hypoglycemia‡ 301/1242 (24.2) 328/1217 (27.0) 0.91 (0.80–1.04)
At 6 hr after birth 92/1224 (7.5) 123/1194 (10.3) 0.73 (0.56–0.95)
At 36 hr after birth 54/1035 (5.2) 62/999 (6.2) 0.85 (0.60–1.21)
Severe intraventricular hemorrhage 6/810 (0.7) 3/720 (0.4) 1.85 (0.46–7.42)
Apgar score <7 at 5 min after birth 276/1359 (20.3) 293/1368 (21.4) 0.95 (0.82–1.10)
Major resuscitation at birth 101/1382 (7.3) 144/1383 (10.4) 0.70 (0.55–0.88)
Use of oxygen therapy‡ 726/1429 (50.8) 756/1413 (53.5) 0.95 (0.88–1.02)
Use of CPAP‡ 265/1429 (18.5) 337/1413 (23.9) 0.78 (0.67–0.90)
Use of mechanical ventilation‡ 83/1284 (6.5) 103/1264 (8.1) 0.79 (0.59–1.05)
Use of parenteral therapeutic antibiotics 
for ≥5 days§
527/1245 (42.3) 494/1175 (42.0) 1.00 (0.91–1.10)
Use of surfactant‡ 9/1284 (0.7) 18/1264 (1.4) 0.49 (0.22–1.08)
Admission to a special care unit 905/1287 (70.3) 897/1268 (70.7) 0.99 (0.94–1.04)
Readmission 39/1429 (2.7) 48/1413 (3.4) 0.81 (0.53–1.25)
Maternal outcome
Death 5/1429 (0.4) 4/1423 (0.3) 1.23 (0.33–4.57)
Fever 78/1417 (5.5) 70/1406 (5.0) 1.10 (0.80–1.50)
Chorioamnionitis 17/1429 (1.2) 18/1423 (1.3) 0.93 (0.48–1.80)
Endometritis 5/1429 (0.4) 3/1423 (0.2) 1.65 (0.39–6.92)
Wound infection 8/1429 (0.6) 15/1423 (1.1) 0.53 (0.22–1.25)
Nonobstetrical infection 34/1429 (2.4) 42/1423 (3.0) 0.81 (0.52–1.26)
Use of therapeutic antibiotics 68/1427 (4.8) 89/1422 (6.3) 0.76 (0.56–1.03)
Any antibiotic use 1205/1353 (89.1) 1216/1355 (89.7) 1.00 (0.97–1.02)
Postpartum readmission 14/1429 (1.0) 13/1423 (0.9) 1.07 (0.50–2.26)
*  CPAP denotes continuous positive airway pressure.
†  The 95% confidence intervals are not adjusted for multiplicity and should not be used to infer definitive treatment effects.
‡  This outcome was measured from the initial postnatal hospitalization until death, discharge, or completed day 7 (which-
ever came first).
§  This category includes the use of parenteral therapeutic antibiotics in neonates for 5 days or more, even if interrupted, 
except for the use in those who died before 5 completed days. Referral of live-born infants for treatment was not included 
because of very few events.
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ACT intervention clusters had a birth weight below 
the fifth percentile. The low incidence of appar-
ent preterm birth among infants exposed to 
dexamethasone in ACT indicates substantial 
overtreatment, which may explain at least in part 
the lack of mortality benefit and overall harm 
observed. Appropriate selection of participants 
and the provision of a minimum standard of care 
appear to be critical in achieving benefits and 
preventing potential harms from glucocorticoids 
and should be incorporated into future implemen-
tation strategies.
The results of our trial provide reassurance 
regarding the beneficial effects of glucocorti-
coids with respect to reducing neonatal mortal-
ity in low-resource settings, and they expand the 
scarce body of evidence from low- and middle-
income countries.16-20 Although smaller trials con-
ducted in low- and middle-income countries have 
suggested benefits, most of them were not pla-
cebo-controlled trials.17,19,20
The use of dexamethasone in our trial did not 
increase the risk of maternal or neonatal infec-
tion; this finding is consistent with those of 
previous trials conducted in low- and middle-
income countries,16-20 where the baseline risks of 
such infections are high.21-23 The lack of effect on 
the overall incidence of neonatal hypoglycemia 
and the suggestion of a reduced risk of early 
hypoglycemia with the use of dexamethasone, 
however, were unexpected. Studies in animals 
and pharmacokinetic studies have indicated that 
neonatal hypoglycemia is a potential complica-
tion of the use of standard doses of dexametha-
sone.24 Moreover, in the Antenatal Late Preterm 
Steroids trial, the administration of betametha-
sone to women with a singleton pregnancy at 34 
weeks 0 days to 36 weeks 5 days of gestation 
who were at risk for preterm birth increased the 
incidence of neonatal hypoglycemia by 60%.25 
The effects of maternal glucocorticoid adminis-
tration on preterm infants have been inconsis-
tent across studies26,27 and may differ in infants 
with early preterm birth and those with late 
preterm birth.
The current trial is larger than previous pla-
cebo-controlled trials assessing the efficacy and 
safety of antenatal glucocorticoids in low-resource 
countries, and we used broad eligibility criteria. 
We assessed neonatal death according to the 
standard definition (which was largely unspeci-
fied or restricted to in-hospital deaths in previ-
ous trials7), and we carefully selected hospitals 
that could reasonably meet minimum precondi-
tions for glucocorticoid use. The loss to follow-
up of trial participants and the percentage of 
participants with missing primary outcome data 
were very low despite the need for follow-up in 
the community. The trial was limited by the 
challenges in standardizing maternal and neo-
natal care across trial sites and the use of ultra-
sonographic examination to assess gestational 
age for a substantial percentage of the partici-
pants in the third trimester.
Further study is warranted to determine the 
most appropriate dosing regimen28,29 and the 
safety and efficacy of administering glucocorti-
coids in late preterm pregnancy,30 particularly in 
low-resource countries. The observed benefits 
with respect to neonatal mortality appeared to 
increase with tocolysis and with the duration of 
fetal exposure to dexamethasone; the role of toco-
lytic agents in safely delaying early preterm birth 
in women who are eligible for the use of ante-
natal glucocorticoids also merits further inves-
tigation.
The use of antenatal dexamethasone that was 
targeted to women at risk for imminent preterm 
birth in hospitals with minimum resources for 
maternal and preterm newborn care resulted in 
significantly lower risks of neonatal death and 
stillbirth or neonatal death than did the use of 
placebo, without any evidence of harm to wom-
en or newborns.
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